








Stem Cell Reports, Volume 8






Supplemental Information


Patient iPSC-Derived Neurons for Disease Modeling of Frontotemporal Dementia with Mutation in *CHMP2B*

Yu Zhang, Benjamin Schmid, Nanett K. Nikolaisen, Mikkel A. Rasmussen, Blanca I. Aldana, Mikkel Agger, Kirstine Calloe, Tina C. Stummann, Hjalte M. Larsen, Troels T. Nielsen, Jinrong Huang, Fengping Xu, Xin Liu, Lars Bolund, Morten Meyer, Lasse K. Bak, Helle S. Waagepetersen, Yonglun Luo, Jørgen E. Nielsen, The FReJA Consortium, Bjørn Holst, Christian Clausen, Poul Hyttel, and Kristine K. Freude


A**B****C****D**




A**B****C****D****E**

A**B**

FTD3 Neurons



Isogenic Controls



SUPPLEMENTAL FIGURE LEGENDS

Figure S1. Basic Characterisation of iPSCs, Related to Figure 1. (A) qPCR analysis of pluripotency genes in FTD3 iPSCs relative to H1 human ESCs. (B) ICC of FTD3 iPSCs for pluripotency marker proteins. Scale bars, 200 μm for all. (C) ICC of FTD3 iPSCs with β III-TUBULIN (ectoderm), α -SMA (mesoderm), and AFP (endoderm) after EB differentiation. Scale bar, 200 μm for all. (D) Karyotype analysis of FTD3 iPSCs and isogenic controls showing no abnormalities.

Figure S2. Forebrain Identity of NPCs and Differentiation into Cortical Neurons, Related to Figure 1. (A) Flow cytometry assay for NESTIN and SOX1 in the FTD3 NPCs and isogenic controls. (B) Immunocytochemistry (ICC) assay of NPCs for NESTIN and forebrain progenitor protein markers OTX2 and PAX6. Scale bar, 50 μm . (C) ICC confocal images of FTD3 neurons and isogenic controls: dendritic neuronal protein marker MAP2 coupled with axonal protein marker TAU, glial marker GFAP, cortical markers TBR1 and CTIP2, axonal neuronal protein marker TUJ1 coupled with glutamatergic neuron marker VGLUT1, GABAergic neuron marker GABA and dopaminergic marker TH. Scale bars, 50 μm for all and 15 μm for TUJ1 coupled with VGLUT1.

Figure S3. Functional Characterization of Cortical Neurons, Related to Figure 1. (A) Intracellular calcium kinetics in FTD3 neurons (H150, H151, H242) and isogenic controls (H150 ISO, H151 ISO, H242 ISO). (B), (C), (D) and (E) Electrophysiological properties of FTD3 neurons and isogenic controls: (B) action potentials activated by current steps; (C) spontaneous elicited action potentials; (D) whole-cell currents activated by a series of voltage steps: in some recordings, excitatory postsynaptic potentials (EPSP) were observed at negative potentials as demonstrated in the enlarged portion of the recording; (E) representative image of patched cells. Scale bar, 300 μm

for all.

Figure S4. TEM Overview Image of Neurons and p62 Aggregates Characterization in the Neural Culture, Related to Figure 2-4. (A) Images represent initial segment of an axon and a portion of the nucleus. In the FTD3 neurons, endosome-like structures (*) and mitochondria (x) accumulate, and the arrangement of microtubule structures (indicated by triangle arrow) is perturbed compared with isogenic controls. Scale bar, 2 μm for all. (B) Immunostaining for p62 and the neuronal marker protein TUJ1, glial marker protein S100 β in FTD3 neural cultures and isogenic control. Red box indicates area with cells having p62 positive aggregates. DAPI was used as a nuclear marker. Scale bar, 20 μm for all.

Table 1A

Summary of Characterization of All hiPSC Lines Used in The Current Study				
hiPSC Line	Genotype	Karyotype	Pluripotency-associated Marker	Gender
H150	G/C 31449 in <i>CHMP2B</i>	Normal	+	M
H151	G/C 31449 in <i>CHMP2B</i>	Normal	+	M
H242	G/C 31449 in <i>CHMP2B</i>	Normal	+	F
H150 ISO	Gene correction	Normal	+	M
H151 ISO	Gene correction	Normal	+	M
H242 ISO	Gene correction	Normal	+	F
H256 C6	Wild-type	Normal	+	M

Table 1B

Primers for qPCR			
Gene Name	Gene ID (GI)	Forward	Reverse
OCT4	553727227	CCCCAGGGCCCCATTTTGGT ACC	ACCTCAGTTTGAATGCATGG GAGAGC
SOX2	325651854	TTCACATGTCCCAGCACTAC CAGA	TCACATGTGTGAGAGGGGCA GTGTGC
NANOG	663071048	AAAGAATCTTCACCTATGCC	GAAGGAAGAGGAGAGACAG T
GDF3	10190669	TGACCATCTCCCTCAACAGC	TACCCACACCCACACTCATC
TRPC6	170014741	ATCCAGTCATGACGGCTTTA G	TCTGCACAGATCAAGGAGTC
HFE	91718876	TGTTCACTGTTGACTTCTGG AC	ATCATACCCGTA CTTCCAGT AG
HO-1	298676487	ATGGAGCGTCCGCAACCCGA C	TGAAGCCGTCTCGGGTCACC TG
ABCG2	62526032	ACAGCTTCCAATGACCTGAA	GTTGAGACCAGGTTTCATGA

		GG	TC
FLVCR2	190341090	ACATTGAAGACCGGGACGAGC	TCAAGGCATAGCTCAGGGATG
CP	189458860	TGGGATTATGCCTCTGACCATG	AGGTTTCATCTGTGTACTGAG
HP	531034758	ACTCGTCCCTATAACCATCCAC	TTCTGGAATGGTCCAGTTGTAG
APOE	705044057	TGGTCACATTCCTGGCAGGATG	TAATCCCAAAGCGACCCAGTG
LRRK2	171846277	TCACGTACTCCGAGCGCGCCTC	CTGCTGCACACTCGCGACTCTC
GAPDH	576583510	ACCACAGTCCATGCCATCAC	TCCACCACCCTGTTGCTGTA
EIF6A	392494081	AAGTCTTCAGACAGACAGTGGCCGACCAG	ACCACCATCCCAGCAGCAATCACCT
CHMP2B	170650589	Common forward primer: GACATCTTTGACGGTTCTGA	
CHMP2B			Wild-type specific reverse primer: GAGCTTTGGCCATCTTTC
CHMP2B			Intron5 specific reverse primer: GAAAAGATGATGTTTCATACCTTTC
CHMP2B			Delta10 specific reverse primer: CAGCTGATGGAGCTTTC

Table 1C

List of Antibodies		
Antibody Name	Dilution	Vendor and Catalog Number
OCT4	1/500	Santa Cruz, sc-8628
NANOG	1/500	Peprtech, 500-P236
SSEA4	1/100	Biologend, 330402
TRA-1-60	1/200	Biologend, 330602
TRA-1-81	1/200	Biologend, 330702

NESTIN	1/1000	Millipore, MAB5326
OTX2	1/500	R&D, AF1979
PAX6	1/300	Covance, PRB-278P
MAP2	1/500	Sigma, M1406
TUJ1	1/500	Covance, MRB-435P
TAU	1/200	Dako, A0024
GFAP	1/400	Dako, Z0334
TBR1	1/300	Abcam, ab31940
CTIP2	1/200	Abcam, ab28448
VGLUT1	1/500	Synaptic Systems, 135303
GABA	1/200	Sigma, A2052
TH	1/500	Pel-Freeze Biologicals, P40101-0
S100 β	1/1000	Abcam, ab11178
P62	1/200	Progen, GP62-C
TRPC6	1/1200	Alomone Labs, ACC-017
β -Actin	1/5000	Sigma, A5441
IRDye [®] 680LT	1/15000	LI-COR, 926-68023
IRDye [®] 800CW	1/15000	LI-COR, 32212

SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Ethical Statement

The study was approved by the Ethics Committee of the Capital Region of Denmark (H-4-2011-157), and written informed consent was obtained from each participant before enrollment.

Cell Culture, iPSC Generation and Neuronal Differentiation

Human dermal fibroblasts cultures were obtained from skin biopsies from two symptomatic (H150, H151) and one presymptomatic (H242) FTD3 individuals (all from the same family), as well as one healthy unrelated individual (H256). The FTD3 individuals were carriers of the G-to-C transition at the 5' acceptor splice site of *CHMP2B* exon 6 on chromosome 3 (Skibinski et al., 2005). Fibroblasts were cultured in DMEM supplemented with 1% GlutaMAXTM, 10% FBS and 1% Penicillin-Streptomycin. For the generation of iPSCs, one microgram of reprogramming plasmid mixtures was electroporated into 1×10^5 fibroblasts using the Neon[®] transfection system (Thermo Fisher Scientific, USA) with a 10 μ L kit according to the manufacturer's instructions. The plasmid mixtures used in this experiment were pCXLE-hOCT3/4, pCXLE-hSK and pCXLE-hUL (Addgene, 27077, 27078, 27080) (Okita et al., 2011). Electroporation conditions were as followed: 1,200 V, 20 ms, 2 time pulses. After transfection, 5×10^4 cells were distributed onto 35-mm dishes coated with Matrigel (BD Biosciences, USA) and cultured in DMEM, 1% GlutaMAXTM, 10% FBS without bFGF and Penicillin-Streptomycin. The culture medium was replaced the next day and supplemented with bFGF, Penicillin-Streptomycin and cultured at 5% O₂, 5% CO₂ and 90% N₂. On day 3 to 4 depending on confluence, the culture medium was replaced with ESC medium consisting of Essential 8TM basal medium with supplement (Thermo Fisher Scientific, A1517001), 100 μ M Sodium Butyrate and 0.1% Penicillin-Streptomycin. The colonies were manually picked 21–28 d

after plating, and those colonies morphologically similar to human embryonic stem cells (ESCs) were selected for further cultivation and evaluation. When confluent, iPSC were passaged 1:3-6 with 0.5 mM EDTA on to VitronectinTM (Thermo Fisher Scientific, A14700)-coated 6-well dishes. The hiPSC clones used in this study are summarized in Table S1A. Mutation status was confirmed by Sanger sequencing.

iPSC lines were differentiated toward neural-specific progenies in 6-well plate wells (NUNC, USA) pre-coated with Matrigel[®] (BD Biosciences, 354277) in a 21% O₂ 5.0% CO₂ 37°C incubator employing a modified dual SMAD protocol (Shi et al., 2012). Cells were expanded in E8 medium until around 100% confluence was reached. Neural induction was initiated by changing the medium to neural basic medium consisted of 50% DMEM/F-12 medium, 50% Neural basal medium (Thermo Fisher Scientific, 10888-022), N2 (Thermo Fisher Scientific, 17502-048), B27 without Vitamin A (Thermo Fisher Scientific, 12587-010), supplemented with SB431542 a small molecule inhibitor of the TGFβ pathway (Selleck, S1067) and LDN193189 an inhibitor of the BMP pathway (Selleck, S2618). The duration of this initial neural induction was 10 to 12 days. Subsequently, cells were split onto poly-O-Lysine/laminin (Sigma, L2020) pre-coated 6-well plate wells and remained in the neural induction medium overnight. Expansion of the neural progenitor cells, for cryopreservation and subsequent terminal differentiation was achieved by proliferating these cells in neural basic medium supplemented with 10 ng/ml bFGF. Neuronal maturation was achieved by addition of the following media: Neural basic medium supplemented with 20 ng/ml BDNF (Cell Guidance Systems, GFH1-10), 10 ng/ml GDNF (Cell Guidance Systems, GFH2-10), 50 μM db-cAMP (Sigma, D0627) and 200 μM L-Ascorbic acid 2-phosphate (Sigma, A8960). One week after terminal differentiation cells were replated again for further maturation.

Genome Editing

Generation of isogenic controls was achieved via the CRISPR/Cas9 system using single-strand donor oligonucleotides (ssODNs) as templates for single nucleotide repairs.

Isogenic gene-corrected controls were obtained using the CRISPR/Cas9 system in combination with ssODNs as homologous templates covering the mutation site. The ssODNs were designed with silent mutations that both prevent recutting of the CRISPR/Cas9 and create a restriction enzyme recognition site for SacII to enable screening for recombinant clones. The CRISPR/Cas9 vectors were generated following the protocol from Ran et al. (Ran et al., 2013). At a confluency of 80%, the iPS cells growing in a 10-cm plate were incubated with Accutase for 5 – 10 minutes at 37 °C. iPS cells were harvested and centrifuged. 2 million cells were co-transfected with 10 µg of the CRISPR/Cas9 plasmid (Addgene, 62988) and 1 µL of 100 ng/µL of the ssODNs. We used a 4D nucleofector (program CA167) from Amaxa in combination with the P3 Primary Cell Kit for transfection. Transfected cells were plated on a 10 cm dish coated with Matrigel. After one day, Puromycin (Thermo Fisher Scientific, A1113803) was added for 2 days in a 1:50000 dilution. After selection, Puromycin was withdrawn. Around 4 - 8 days after selection, resistant iPS colonies were picked and transferred to a cell culture 96 well plate. When the wells became confluent, iPS cells were split into a DNA isolation plate and a 96 well cell culture dish for further cultivation. DNA was isolated using the prepGEM™ Kit (zyGEM, PTI0500). Subsequently, a PCR was performed with primer pair P1-FW and P1-RV. PCR products were digested with SacII for 30 – 60 minutes at 37 °C. Positive clones were sequenced to confirm gene-editing of *CHMP2B*.

Quantitative qPCR

RNA was extracted using RNeasy® Plus Mini Kit (Qiagen, 74134) according to the manufacturer's protocol. cDNA was synthesized from 1 µg of total RNA in 20 µL reaction using iScript™ cDNA synthesis Kit (BIO-RAD, 1708890). After synthesis, the cDNA was diluted five

times with double distilled water and stored at -20°C . Quantitative RT-PCR (qPCR) reactions were done in triplicates using the FastStart Lightcycler 480 SYBR Green I Master (Roche, 04707516001) on LightCycler[®] 480 real-time PCR system (Roche, Switzerland). cDNA samples were subjected to PCR amplification with primers for *OCT4*, *SOX2*, *NANOG*, *GDF3* and *GAPDH* (**Table S1B**). A commercial ESCs line H1 (Wicell, USA) was used as a positive control.

Quantification of *CHMP2B* RNA Transcripts

Half a microgram of RNA was subjected to first strand synthesis using random hexamer primers and SuperScript III Reverse Transcriptase (Invitrogen) in accordance with the manufacturer's instructions. PCR reactions were assembled using 5 μl of Brilliant III ultra-fast SYBR Green qPCR master mix (Agilent Technologies), 0.5 μl of forward primer (10 μM 0.5 μl of reverse primer (10 mM), 2 μl of water, and 2 μl of cDNA template. The PCR program was as follows: 2 min at 50°C , 10 min at 95°C and then 40 cycles of 15 s at 95°C , 30 s at $58\text{-}60^{\circ}\text{C}$ (dependent on primers) and 1min at 72°C . To distinguish the three different isoforms of *CHMP2B*, a common forward primer was used with either one of the three isoform specific reverse primers. The sequences of the primers were listed in Table S1B. For normalization, primers detecting the housekeeping gene *EIF6* were used. *CHMP2B* specific primers were used at an annealing temperature of 58°C , whereas the *EIF6A* primer pair was used at 60°C .

The relative abundance of the *CHMP2B* WT transcript between the different cell lines was calculated by normalization to *EIF6* employing the relative standard curve method. The relative abundance of the three different isoforms of *CHMP2B* within each cell line was calculated by constructing standard curves from serial dilutions of a single plasmid holding all three amplicons in a stoichiometry of 1:1:1. This way we were able to calculate the exact amount of each isoform in relation to one another within in each cell line using the relative standard curve method.

Immunocytochemistry and Confocal Microscopy

For the immunofluorescence staining, cells were fixed with 4% formaldehyde in Dulbecco's Phosphate-Buffered Saline (DPBS) for 15 min, permeabilized with 1% Triton X-100 in DPBS for 15 min, and blocked with 2% bovine serum albumin in DPBS for 1 h. Thereafter, cells were incubated with the following primary antibodies (Table S1C) for 1 h. Primary antibodies were detected using secondary antibodies conjugated to Alexa Fluor 488 (1:500; Molecular Probes), Alexa Fluor 594 (1:500; Molecular Probes) and Alexa Fluor 647 (1:500; Molecular Probes). Cells were washed in DPBS and stained with DAPI (Sigma-Aldrich, D9542). Fresh DPBS was replaced and cells were imaged immediately using sequential line scanning with a Leica TCS SP5 II inverted CLSM or Z-stack recording with a Zeiss LSM 710 CLSM equipped with UV laser, Argon laser and AOBS beam splitter.

Flow Cytometry

To verify purity and similar proportions of marker positive hNPCs from each differentiated cell line, intracellular markers of hNPCs were analyzed by flow cytometry. When the hNPCs reached 80%–90% confluence, cells were dissociated using TrypLE™ Express (Thermo Fisher Scientific, 12605010) and incubated with Fixation/Permeabilization Working Solution (eBioscience, 88-8824) at room temperature for 60 mins. After centrifuging, the supernatant was discarded and cell pellets were resuspended in 1× Permeabilization Buffer containing monoclonal antibodies against NESTIN (BD Pharmingen, 560393) and SOX1 (BD Pharmingen, 561592). After 45 min of incubation in the dark at room temperature, cells were washed with fresh 1× Permeabilization Buffer, and resuspended in Flow Cytometry Staining Buffer (eBioscience, 00-4222) at a density of 1×10^6 cells/ml. Subsequently, they were analyzed by the CSampler™ Flow Cytometer (BD

Accuri™, USA). Unlabeled samples were used as controls for gating. Data was analyzed using the FlowJo software (version 10.0).

Whole-cell Patch Clamp Recording

Whole-cell current-clamp and voltage-clamp measurements were performed on FTD3 neurons and isogenic controls after terminal differentiation from hNPCs for 5 weeks by using a MultiClamp 700B amplifier and MultiClamp Commander (Axon Instruments, Molecular Devices, USA). Patch pipettes were fabricated from borosilicate glass capillaries (1.5mm O.D., Fisher Scientific) on a gravity puller (Model PP-830, Narishige, Japan) and had a final tip resistance of 2–3 M Ω . Recordings were performed at $36\pm 1^\circ$ C in extracellular solution containing (in mM): NaCl, 125; HEPES, 10; NaH₂PO₄, 1.25; MgCl₂, 1; CaCl₂•2H₂O, 2; glucose, 25; pyruvic acid, 3 (pH 7.4, 290 mOsm) and patch pipettes were filled with intracellular solution containing (in mM): K-gluconate, 135; NaCl, 7; MgCl₂, 2; HEPES, 10; Na₂-ATP, 2; Na₂-GTP, 0.3 (pH 7.2, 270 mOsm). The recording conditions were modified from Shi et al., 2012 (Shi et al., 2012). Spontaneous mini excitatory/inhibitory postsynaptic or action potential activity was monitored for 1 min. The membrane potential was adjusted to approximately -60 mV followed by stepwise current injections from 0 pA to +50 pA. Voltage-clamp recordings were performed from a holding potential of -110 mV. Currents were activated by a series of depolarizing steps ranging from -90 mV to +30 mV. All analog signals were acquired at 50 kHz, filtered at 6 kHz, digitized with a Digidata 1440 converter (Axon Instruments, Molecular Devices) and stored using pClamp10 software (Axon Instruments, Molecular Devices). Recordings were corrected for a -14 mV junction potential and data were analyzed using Clampfit 10 software (Axon Instruments, Molecular Devices).

Recordings of Intracellular Calcium Kinetics

Recordings of intracellular calcium kinetics were performed on FTD3 neurons and isogenic controls after terminal differentiation from hNPCs for 5 weeks. Neurons cultured in 96-well plates were loaded for 1 h at 37°C with 100 µL of the fluorescent calcium indicator, Calcium 5 (Molecular Devices, USA) dissolved in Hanks Balanced Salt Solution (HBSS; Thermo Fisher Scientific) with 20 mM HEPES and 1.26 mM CaCl₂ to 1/3 of the concentration suggested by provider. Recordings were performed at 37°C in a FDSS 7000 fluorescence kinetics plate reader (Hamamatsu Photonics, Japan). The excitation wavelength was 480 nm; the emission wavelength was 540 nm and the sampling frequency 1 Hz. Compound dilutions were prepared in assay buffer and 20 µl applied with 10 min intervals. Baseline fluorescence was recorded for 10 min before application of 300 µM glutamate/10 µM glycine, 100 µM Serotonin (5-hydroxytryptamine, 5-HT), 25 mM K⁺, 100 µM GABA, 100 µM Dopamine (DA), and 300 µM acetylcholine (ACh). The fluorescence was normalized to the first data point of each of the traces.

Morphometric Analyses

Images of beta tubulin III-immunoreactive cells were recorded (12 images/cell line) using a bright field microscope (×200) connected to a digital camera (Leica). Average neurite length and soma size were assessed on coded images (experimenters 'blinded' to sample identity) using the software ImageJ (version 1.50e) and the plugin NeuronJ (version 1.4.3). Only cells displaying an intense beta tubulin III immunostaining and a neuronal morphology (well-preserved cell soma and ≥ 1 primary neurite) were included in the analyses. Results are expressed as mean values ± SEM from 129-515 neurons per cell line.

Transmission Electron Microscopy

Cells were seeded on 13 mm Thermanox™ plastic coverslips (NUNC, 174950) coated with poly-O-Lysine/laminin. Cells were fixed with 3% glutaraldehyde (Merck, 1042390250) in 0.1 M Na-phosphate buffer, pH 7.4, post-fixed in 1% osmium tetroxide in 0.1 M Na phosphate buffer, dehydrated stepwise in a graded ethanol series, and embedded in Epon (TAAB, T031). Semi-thin (2 µm) sections were cut with a glass knife (KnifeMaster II, LKB Bromma 7800) on an ultramicrotome (Leica Ultracut, Leica Microsystems, Wetzlar, Germany), stained firstly with 1% toluidine blue O (Millipore, 1159300025) and 1% Borax (LabChem, LC117101). Ultra-thin (50 nm to 70 nm) sections were sectioned with a diamond knife (Jumdi, 2 mm) on an ultramicrotome (Leica Ultracut), contrasted with 2% uranyl acetate (Polyscience, 21447) and lead citrate, and examined using a Philips CM100 transmission electron microscope equipped with a Morada camera.

Oxidative Stress Assay

Reactive oxygen species (ROS) production was quantified in FTD3 neurons and isogenic controls using CellROX® Green Flow Cytometry Assay kit (Thermo Fisher Scientific, C10492). Staining was carried out according to the manufacturer's instructions, and stained cells were dissociated from the plate using Accutase and immediately analyzed by flow cytometry using CSampler™ Flow Cytometer (BD Accuri™, USA).

Apoptosis Assay

Activated Caspases 3 and 7 in apoptotic cells was quantified in FTD3 neurons and isogenic controls using CellEvent® Caspase-3/7 Green Flow Cytometry Assay kit (Thermo Fisher Scientific, C10427). Staining was carried out according to the manufacturer's instructions, and labeled cells were dissociated from the plate using Accutase and immediately analyzed by flow cytometry using

CSampler™ Flow Cytometer (BD Accuri™, USA).

Seahorse XF⁹⁶ Mitochondria Respiration Assay

Oxygen consumption rate (OCR) was measured using a Seahorse XF⁹⁶ Extracellular Flux Analyzer (Seahorse Biosciences, USA). FTD3 hNPCs and isogenic controls were seeded in a Seahorse 96-well cell culture microplate at a density of 6.5×10^3 cells/well for neuronal maturation. On the day of the assay, the culture media was changed to unbuffered DMEM (pH 7.4) supplemented with 2.5 mM glucose and the cells were equilibrated for 10 min at 37 °C in a CO₂-free incubator. The pH of the reagents used to test mitochondrial function was adjusted to 7.4 on the day of assay. The OCR measurement cycle consisted of 3-min mix and 3-min measurement of the oxygen level. Test of mitochondrial function was initiated by three baseline OCR measurement cycles. These were followed by the sequential injection of the inhibitor of ATP synthase, Oligomycin (2 μM final concentration); the uncoupling agent, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP, 1 μM); a mixture of the inhibitors of mitochondrial complexes I and III, Rotenone (0.5 μM) and Antimycin A (0.5 μM) with one OCR measurement cycle in between each injection and two final measurement cycles. Oxygen consumption rates were automatically recorded and calculated by the Seahorse XF⁹⁶ software, Wave. Subsequent to the Seahorse analysis, the protein content was measured for each well using the Pierce assay with bovine serum albumin as standard. Results are expressed as mean values ± SEM from 12 wells/plate obtained in triplicate for each condition. Mitochondrial respiration parameters were calculated as follows: *basal respiration*, non-mitochondrial respiration (minimum measurement after rotenone/antimycin injection) was subtracted from the last measurement obtained before oligomycin injection; *proton leak*, non-mitochondrial respiration was subtracted from the measurement after oligomycin injection; *maximal respiration*, measurement obtained after FCCP

injection; *spare respiratory capacity*, basal respiration subtracted from maximal respiration; *ATP production*, measurement after oligomycin injection was subtracted from the last measurement before oligomycin injection.

MitoTracker[®] Assay

Cells for MitoTracker[®] Red CMXRos (Molecular Probes, M7512) analysis were cultured on 0.17 μm glass coverslips coated with poly-O-Lysine/laminin. When ready for staining, cells were incubated with 50 nM MitoTracker[®] in DMEM/F-12 medium for 15 min in 37 °C. Following, fixation in 4% paraformaldehyde in DPBS, permeabilization in 0.5% Triton X-100 in DPBS for 15 min, incubation with DAPI for 10 min in room temperature. In between each step the samples were washed 3 times in DPBS. After the last wash, the glass coverslips were mounted with mounting media and sealed onto slides. Images were acquired by laser scanning confocal microscopy (Zeiss LSM 710).

RNA Sequencing Analysis

For deep RNA sequencing, libraries of FTD3 neurons, isogenic controls and one independent healthy control were prepared and sequenced independently on HiSeq 2000 Sequencing System (Illumina, USA). For library construction, after extracting the total RNA from samples, mRNA and non-coding RNAs are enriched by removing rRNA from the total RNA with kit. By using the fragmentation buffer, the mRNAs and non-coding RNAs are fragmented into short fragments (about 200-500 nt), then the first-strand cDNA is synthesized by random hexamer-primer using the fragments as templates, and dTTP is substituted by dUTP during the synthesis of the second strand. Short fragments are purified and resolved with EB buffer for end reparation and single nucleotide A (adenine) addition. After that, the short fragments are connected with adapters, then

the second strand is degraded using UNG(Uracil-N-Glycosylase) finally. For data processing, Illumina Casava1.8 software was used for base calling. Clean reads were obtained by filtering reads with adaptor sequences and low quality reads. Clean reads that aligned to rRNA were removed. After removing reads aligned to rRNA, we used SOAP2 to align clean reads to the hg19 UCSC RefSeq (RNA sequences, GRCh37) (para: -m 0 -x 1000 -s 40 -l 32 -v 5 -r 2 -p 4). Gene level expression was performed by transforming uniquely mapped transcript reads to TPM. Normalized differentially expressed genes were detected. Genes whose expression changes are more than 1.5 folds with FDR < 5% identified in FTD3 neurons compared to isogenic controls were submitted to Gene ontology (GO) enrichment analysis. GO enrichment analysis of assembled transcripts was performed with ClueGO v1.4 (Bindea et al., 2009) using the following parameters: use GO term fusion; enrichment/depletion two-sided hypergeometric statistical test; correction method: Benjamini-Hochberg; GO term range levels: 3-8; minimal number of genes for term selection: 10; minimal percentage of genes for term selection: 10%; κ -score threshold: 0.5; general term selection method: smallest p value; group method: κ ; minimal number of subgroups included in a group: 3; minimal percentage of shared genes between subgroups: 50%. For qPCR validation of the RNA sequencing results, we performed independent neuronal differentiation experiments and examined key gene expression, and all primer sequences for these genes are listed in **Table S1B**.

Western Blotting

Cell pellets from FTD3 neurons and isogenic controls were lysed in mPER™ mammalian protein extraction reagent (Thermo Fisher Scientific, 78501) containing protease inhibitor (Complete tablets, Roche 11873580001) and phosphatase inhibitors (PhosSTOP tablets, Roche 04906845001). 10 μ g of protein were separated by NuPAGE™ Novex™ 4-12 % Bis-Tris mini gel

(Thermo Fisher Scientific, NP0335BOX) followed by immunoblotting with rabbit anti-TRPC6 (Alomone Labs, ACC-017) and mouse anti- β -Actin (Sigma, A5441) primary antibodies, donkey-anti-rabbit IRDye[®] 680LT (LI-COR, 926-68023) and donkey-anti-mouse IRDye[®] 800CW (LI-COR, 32212) secondary antibodies. Immunoblots were developed by Odyssey[®] Fc Imaging System (LI-COR) and data was processed using the software ImageStudio version 5.2.5. Expression levels of TRPC6 were normalized to β -Actin.

Ferrous Iron Assay

Cell pellets were obtained from FTD3 neurons and isogenic controls. An iron assay kit (Abcam, ab83366) was subsequently used to quantify ferrous iron (Fe^{2+}) in the neurons according to manufacturer's instructions. Briefly, cell pellets were homogenized with 120 μL iron assay buffer and supernatants were collected. 20 μL cell supernatant was used for the assay and volume was adjusted to 100 μL with iron assay buffer. Then, 100 μL of the iron probe solution was added producing a Fe^{2+} -Ferene S complex that absorbs light at 593 nm. Infinite[®] 200 PRO Multimode Reader (TECAN, Switzerland) was used to detect absorbance at this wavelength.

Statistical Analysis

Data are presented as mean \pm standard errors (S.E.). “n” is the number of independent differentiations of NPCs (from the cryobank) to neurons. Significance of data was evaluated by Student's *t* test or two-way ANOVA with Bonferroni *post hoc* test. Unless noted otherwise, $P < 0.05$ was considered statistically significant.

Supplemental References

- Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.H., Pages, F., Trajanoski, Z., and Galon, J. (2009). ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* 25, 1091-1093.
- Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., *et al.* (2011). A more efficient method to generate integration-free human iPS cells. *Nat Methods* 8, 409-412.
- Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* 8, 2281-2308.
- Shi, Y., Kirwan, P., and Livesey, F.J. (2012). Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. *Nat Protoc* 7, 1836-1846.
- Skibinski, G., Parkinson, N.J., Brown, J.M., Chakrabarti, L., Lloyd, S.L., Hummerich, H., Nielsen, J.E., Hodges, J.R., Spillantini, M.G., Thusgaard, T., *et al.* (2005). Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. *Nat Genet* 37, 806-808.